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IN-VITRO THROMBUS FORMATION OF STENT WIRES: ROLE 
OF METALLIC COMPOSITION AND HEPARlN COATING. 
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Acute rhrombus formation continues to occur in stented human 
coronary arteries despite systemic anti-coagulation and 
anti-platelet therapy. 
Hemostasis physiology varies widely bemeen species such that 
extrapolation of animal studies to human clinical trials is 
error-prone. The purpose of &is study was to determine the 
thrombogenic potential cr various metals and to test the 
ability Leparin to diminish this potential. We tested in- 
vitro l$rombus fcJrmation on 0.006’ stent wires (Cook, Inc.) 
composed of stainless steel (SS), copper (CU), heparin-coated 
copper (CUH), titanium (Tl), tantalum (TA), and heparin- 
coated tantalum (TAH). Two cm length wires were incubated in 
5 aI of fresh, rapidly heparinized (1 unit/ml) human venous 
blood from two young, healthy donors for 1 hour (polypropylene 
tubes on a flat rotator at 100 rpm). Wires were removed, rinsed 
in phosphate buffered saline, fixed in 2.5% glutaraldehyde in 
O.lM cacodylate buffer. and examined with scanning electron 
microscopy. SEM photographs were ranked by observers blinded 
to metal content and heparin coating: O-4 for thrombus content 
(area covered: O=O-25%, l= 26.50%, 2 = Sl-75%. 3 = 76-99%. 
4= 1OOY.). Results: Amount of thrombus formation was 
TAH c TA c SS ( CU c Tl c CUH (Kruskal.WallisANOVA, p c 0.0001); 
TA e SS (median test, p = 0.12); TAH < SS (median test, p = 
0.005). 
n: Heparin-coated tantalum shows superior 
inhibition of thrombus formation in-vitro when compared with 
several other metal species. Uncoated tantalum also tends to 
be less thrombogenic although less so than heparin-coated 
tantalum. 
ofmuicrn lntervelluonal 
cvlos. . . 1, the trcatmmt of peripheral vascu- 
attractlve solution. 
CONCLUSION 
Palmas-Schatz Stent shows a high rate of 8ucocs8 in mid-term results. 
3ptJoutof116ptaunderwents s-y. 1 poplIt& restenosL only was 
observed. 
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In splte of an anticoagulation regimen walth high dose heparln. 
phenprocoumon, salicylic acid, dipyrldamole, and infusions of 
low molecular weight dextran a hlgh rate of thrombotic occlu- 
sions occurred during the first days after stent lmplanta- 
tion. In 30 patients treated by coronary stent implantation 
coagulation was monitored by conventional global tests and 
in addition with an enzyme immunoassay for the prothrombln- 
fragment F1+2 (PF) which is a highly sensitive marker for an 
activation of the coagulation system. Normal range of un- 
treated adults Is 0.5-1.0 nmol/l, whereas In patients treated 
with phenprocoumon It should be below 0.5 nmol/l. At the 
first day after implantation uncomplicated cases exhibited PF 
levels not higher than 0.6 nmol/l and did not increase after 
change of treatment from heparin to phenprocoumon. However, 
In patients with acute stent occlusion in the early phase PF 
exceeded 0.6 nmol/l all the time. In these patients an addi- 
tional rise occurred after reduction of heparin which could be 
observed 2 to 3 days before the acute thrombotic occlusion 
resulted. 
Conclusions: PF 1s an useful marker indicating an evolving 
acute occlusion of the stented segment if the measured con- 
centrations at the first days are beyond 0.6 nmol/l. Therefore, 
dose reduction of heparin - even at therapeutic prothrombin 
time ratios - should be avoided if PF 1s not below 0.5 nmol/l. 
Temporary stenting is a new concept aiming to treat abrupt 
closure during PTCA. We studied the immediate and mid term 
results of this new technique in ten patients. 
The temporary stent catheter (TX) is a 3.0 F sinele 
catheter with an expandable stainl‘ess &el mesh. The &nction of 
the wire cage is to suu~ott the vessel wall and maintain flow 
within the lumen thus-avoiding the consequences of abrupt 
closure. 
Between september 1988 and july 199n. the TSC was used in 9 
men and one woman (mean age 59 f 12 years) with acute 
occlusion of the left anterior descending coronary artery (5 cases), 
the right coronary (4 cases) or left circonflex artery (1 case) during 
PTCA, after failure of multiple and repeated inflations. 
Results : In all cases, the TSC restored immediate antegrade 
blood flow while chest pain relieved. For the first patient, the TSC 
was used as a “bail out” device before proceeding to CABG. For 
the 9 remaining patients. the TSC was removed after 30 minutes. 
Late (before dischargi) angiographic control (2 days) was 
excellent in 7 patients. CABG was performed in the 2 other 
patients with one myocaniial infarction. No death occured. 
Follow-up is available for the first 6 patients with angiographic 
control between 2 to 9 months. In 5 patients, the control was 
excellent without angina For the last patient, angina was present 
with a significative stenosis on the left anterior descending artery. 
Conclusion : Temporary stenting is safe and effective in case of 
acute closure during PTCA. CABG may be avoided in most cases 
but an excellent immediate and secundary (before discharge) 
angiographic control is necessary. If angiographic control is not 
perfect, CABG should be performed as soon as possible to 
prevent myocardial infarction. 
